Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Precision BioSciences, Inc. Common Stock

Precision BioSciences, Inc. (Nasdaq: DTIL) is a pre-clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Aliment Capital

The Longevity Fund

RA Capital Management

Leerink Partners

Ridgeback Capital

Alexandria Venture Investments

Cormorant Asset Management

Ditch Plains Capital Management LP

DUMAC

F-Prime Capital

Precision BioSciences, Inc.

Following pre-IND regulatory feedback from the FDA and ex-US regulators, we are advancing PBGENE-HBV toward an IND/CTA filing in 2024. 
 
The goal of our #investigational PBGENE-HBV program is to achieve a functional cure for patients with Chronic Hepatitis B. Hear from Chari Cohen, president of the Hepatitis B Foundation, on what this could mean for those living with HBV.
 
https://bit.ly/48fEVrt

How is ARCUS positioned to move beyond simple gene knockouts and tackle more sophisticated edits like gene elimination, excision, and insertion? 

Hear from Precision CRO, Jeff Smith in his #JPM2024 interview with pharmaphorum as they discuss the future of gene editing with ARCUS and going beyond CRISPR for in vivo gene editing.

Watch:
https://bit.ly/3TXFhQ4

Good news! We’ve completed a licensing deal with TG Therapeutics, Inc. to develop azer-cel for autoimmune diseases.

The deal extends our cash runway into the first half of 2026 and funds our wholly owned In vivo gene editing programs PBGENE-HBV for chronic hepatitis B and PBGENE-PMM for primary mitochondrial myopathy through Phase I Clinical Data.

Precision remains focused on capitalizing on the utility of ARCUS for gene elimination, gene excision and gene insertion through the advancement of our wholly owned and partnered programs.

Read more #JPM24: https://bit.ly/48IqY63

Precision CEO, Michael Amoroso, will speak at Longwood Healthcare Leaders in San Francisco on “The Future of Genetic Therapies” – joining other key industry thought leaders to discuss a wide range of issues affecting biopharma and healthcare. #longwoodhealthcareleaders

Learn more: https://bit.ly/3Tzx7gz

Precision’s Wendy Shoop, PhD., and University of Miami’s Carlos Moraes spoke with BioWorld about the recent publication in Nature Metabolism on mitoARCUS and our #investigational approach to primary mitochondrial myopathy. Read more from their conversation here: https://bit.ly/48g3Bk6

We’re pleased to announce the approval of the first clinical trial application of an ARCUS gene insertion program. Our partner iECURE received clearance from the Australian Therapeutic Goods Administration for a Phase 1/2 trial of ECUR-506, incorporating an ARCUS nuclease for the treatment of OTC deficiency. https://bit.ly/3NsrYDc

At this year’s Hep DART 2023, our Chief Research Officer and co-founder, Jeff Smith, & HBV Research Lead, Emily Harrison, presented on our #investigational PBGENE-HBV program. 

Learn more about our in vivo gene editing: https://bit.ly/41dIegX

We’re proud to share new research published in Nature Metabolism alongside Carlos Moraes that supports the development of mitoARCUS as an in vivo gene editing therapeutic for mitochondrial DNA diseases associated with the m.3243A>G mutation. Read more: https://bit.ly/3tcryK2.

In honor of #Thanksgiving tomorrow we want to thank all our employees for their dedication and celebrate our stakeholders for their investment and belief in Precision. It’s been an active year for us, and we’re looking forward to closing out the year strong.

We’re excited to share that we presented at the Sidoti & Company, LLC November Conference earlier today on our innovative ARCUS technology. ARCUS is capable of more sophisticated gene edits, with a focus on insertions, excisions and eliminations. That is the #ARCUS difference. See a recording of the presentation at the link below: https://bit.ly/3QZ4WWx

	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	6.48M -	10.88M 67.84%	22.24M 104.34%	24.29M 9.20%	115.53M 375.72%	25.10M 78.28%	48.73M 94.15%
cost of revenue
gross profit	6.48M -	10.88M 67.84%	22.24M 104.34%	24.29M 9.20%	115.53M 375.72%	25.10M 78.28%	48.73M 94.15%
selling and marketing expenses
general and administrative expenses	8.02M -	13.67M 70.57%	27.03M 97.66%	36.05M 33.40%	39.69M 10.10%	41.52M 4.62%	39.09M 5.87%
selling general and administrative expenses	8.02M -	13.67M 70.57%	27.03M 97.66%	36.05M 33.40%	39.69M 10.10%	41.52M 4.62%	39.09M 5.87%
research and development expenses	20.32M -	45.12M 122.01%	82.42M 82.65%	98.06M 18.98%	115.24M 17.52%	83.94M 27.16%	53.38M 36.41%
other expenses			-9.76M -
cost and expenses	28.34M -	58.80M 107.46%	109.44M 86.14%	134.11M 22.54%	154.93M 15.52%	125.46M 19.02%	92.46M 26.30%
operating expenses	28.34M -	58.80M 107.46%	109.44M 86.14%	134.11M 22.54%	154.93M 15.52%	125.46M 19.02%	92.46M 26.30%
interest expense			182K -		132K -	1.11M 741.67%	-2.23M 300.72%
ebitda	-20.30M -	-45.56M 124.39%	-87.38M 91.80%	-99.19M 13.52%	-28.81M 70.95%	-98.47M 241.76%	-42.53M 56.81%
operating income	-21.97M -	-47.91M 118.04%	-87.20M 82.01%	-109.83M 25.94%	-39.40M 64.12%	-100.37M 154.72%	-42.53M 57.63%
depreciation and amortization	1.44M -	2.35M 64.04%	-174K 107.39%	10.63M 6,212.07%	10.59M 0.43%	1.89M 82.11%
total other income expenses net	-118K -	1.88M 1,688.98%	-5.67M 402.56%	822K 114.49%	8.80M 970.56%	-11.27M 228.08%	-18.79M 66.73%
income before tax	-21.10M -	-46.04M 118.16%	-92.88M 101.74%	-109.01M 17.37%	-30.60M 71.93%	-111.64M 264.80%	-61.32M 45.07%
income tax expense	-754K -	1.88M 348.67%	-9.58M 610.72%		316K -	11.27M 3,466.77%
net income	-21.10M -	-46.04M 118.16%	-83.30M 80.94%	-109.01M 30.86%	-30.92M 71.64%	-122.91M 297.53%	-61.32M 50.11%
weighted average shs out	33.65M -	49.03M 45.69%	41.99M 14.36%	52.03M 23.91%	58.69M 12.79%	87.90M 49.77%	3.84B 4,270.27%
weighted average shs out dil	33.65M -	49.03M 45.69%	41.99M 14.36%	52.03M 23.91%	58.69M 12.79%	87.90M 49.77%	3.84B 4,270.27%
eps	-0.63 -	-0.94 49.21%	-1.98 110.64%	-2.09 5.56%	-0.53 74.64%	-1.40 164.15%	-0.02 98.86%
epsdiluted	-0.63 -	-0.94 49.21%	-1.98 110.64%	-2.09 5.56%	-0.53 74.64%	-1.40 164.15%	-0.02 98.86%

COM:PRECISIONBIOSCIENCES

Precision BioSciences, Inc.

Last Close

6.50

22/11 21:00

Market Cap

55.69M

Beta: -

Volume Today

105.61K

Avg: -

Preview